In a historic move, Health Canada has granted licenses to three clinics in Toronto and Vancouver to offer psilocybin-assisted therapy for treatment-resistant depression. The psychedelic compound, found in magic mushrooms, will be administered under clinical supervision.
This marks a shift in mental health care, where traditional antidepressants have failed for many. Experts say the therapy offers potential breakthroughs, though critics caution about regulation and misuse.
Mental health professionals in India, Nepal, and Bangladesh are watching closely. While psychedelics remain illegal in South Asia, growing interest in alternative psychiatric treatments is sparking debates on policy flexibility and clinical trials.